Investing News Network

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW31097.26+321.83
S&P 5003825.33+39.95
NASD11127.85+99.11
ASX6539.90-28.20
Commodities
Gold1809.91-0.13
Silver19.89+0.03
Copper3.61-0.10
Palladium1965.07+9.98
Platinum891.26+2.98
Oil108.46+2.70
Heating Oil3.96+0.13
Natural Gas5.620.00
Currencies
BTCUSD19227.50-114.12
USDCAD1.2890+0.0105
USDEUR0.9589+0.0001
USDGBP0.8261+0.0003
USDAUD1.4672-0.0016
USDJPY135.22+0.14

Alpha Cognition Inc.

Alpha Cognition Inc is a clinical-stage biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases such as Alzheimer's Disease and Amyotrophic Lateral Sclerosis. ALPHA-1062 is a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type, with minimal gastrointestinal side effects and novel routes of administration.

×